{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:17:59Z","timestamp":1758050279348,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.jcjo.2013.02.004","type":"journal-article","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T11:19:19Z","timestamp":1380799159000},"page":"e80-e82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regression of choroidal neovascularization in response to systemic chemotherapy for cancer"],"prefix":"10.1016","volume":"48","author":[{"given":"Annie W.","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akrit","family":"Sodhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Eberhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morton F.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2013.02.004_bib1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2013.02.004_bib2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajo.2007.06.039","article-title":"Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients","volume":"144","author":"Brown","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2013.02.004_bib3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200868080-00002","article-title":"Neovascular age-related macular degeneration: potential therapies","volume":"68","author":"Chappelow","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.jcjo.2013.02.004_bib4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1755-3768.2008.01346.x","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients","volume":"87","author":"Pedersen","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2013.02.004_bib5","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2013.02.004_bib6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","article-title":"Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials","volume":"118","author":"Rosenfeld","year":"2011","journal-title":"Ophthalmology"},{"issue":"6 Suppl","key":"10.1016\/j.jcjo.2013.02.004_bib7","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/IAE.0b013e3181ad237a","article-title":"Rationale for combination therapy in age-related macular degeneration","volume":"29","author":"Spaide","year":"2009","journal-title":"Retina"},{"issue":"6 Suppl","key":"10.1016\/j.jcjo.2013.02.004_bib8","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/IAE.0b013e3181ad22d5","article-title":"Combination therapy for age-related macular degeneration","volume":"29","author":"Patel","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2013.02.004_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcjo.2013.02.004_bib10","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418213000872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418213000872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:03:20Z","timestamp":1757793800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418213000872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0008418213000872"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2013.02.004","relation":{},"ISSN":["0008-4182"],"issn-type":[{"type":"print","value":"0008-4182"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regression of choroidal neovascularization in response to systemic chemotherapy for cancer","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2013.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}